The present invention relates to methods of using compounds active on oncogenic Flt3 kinase or Flt3 mutant, such as abnormally activated Flt3 kinase. In one aspect, the present invention provides methods of using compounds of Formula I and all the sub formulas and compounds as described herein that can be used therapeutically and/or prophylactically involving modulation of a Flt3 kinase, slich as an oncogenic Flt3 or Flt3 mutant. In one embodiment, the invention provides a method for treating a subject suffering from or at risk of an oncogenic Flt3 mediated disease or condition.